In the adaptive immune response, immunoglobulins develop that bind specifically to the antigens to which the organism was exposed. Immunoglobulins may bind to known or unknown antigens in a variety of diseases and have been used in the past to identify novel antigens for use as a biomarker. We propose that the immunoglobulins themselves could also be used as biomarkers in antibody-mediated disease. In this proteomic study, rats were immunized with one of two purified antigens, and immunoglobulins from pre-and postimmune sera were analyzed with nano-LC coupled mass spectrometry. It was found that the two treatment groups could be distinguished based on cluster analysis of the immunoglobulin peptides from the immune sera. In addition, we identified 684 specific peptides that were differentially present in one of the two treated groups. We could find an amino acid sequence for 44% of the features in the mass spectra by combining database-driven and de novo sequencing techniques. The latter were essential for sequence identification, as the more common database-driven approach suffers from a poor representation of immunoglobulins in the available databases. Our data show that the development of immunoglobulins during an immune response is not a fully random process, but that instead selection pressures exist that favor the best binding amino acid sequences, and that this selection is shared between different animals. This finding implies that immunoglobulin peptides could indeed be a powerful and easily accessible class of biomarkers.When an immune system is exposed to an antigen, it initiates a specific response to counter the perceived threat. Such a response may consist of cellular and humoral components, including the development and expression of immunoglobulin proteins that have affinity for the antigen. Immunoglobulins, or antibodies, are a family of proteins that consist of conserved constant domains that are important in determining the effector function of the antibody and variable domains that contain hypervariable complementarity determining regions (CDR).
2The CDRs, of which there are three in the immunoglobulin light chain, and three in the heavy chain, form the binding surface for the antigen which evoked the immune response. As such, the CDRs carry the specificity of an immunoglobulin against that antigen.CDRs form during B-cell development in the immune response. A collection of germline genes form a library of components on which the final immunoglobulin sequence will be based. The immunoglobulin genes rearrange, thus selecting a particular combination of germline genes. The CDR1 and CDR2 regions stem from the germline V-genes and can be further modified by somatic mutations. The CDR3 of the light chain lies at the junction of a V-gene and a J-gene and accumulates more variability due to the possible gene combinations. In addition, the junction between V and J gene can be modified by insertions and deletions. Such variation is enhanced even more in the CDR3 of the heavy chain, as it lies on the jun...